Here we will share with you how Cimbi has completed a set of studies aimed at systematically characterizing a PET radioligand known as [11C]SB207145, which binds to the serotonin type 4 receptor (5-HT4R). From the determination of how to quantify the signal from [11C]SB207145 PET scans to initial evidence that it may also represent a proxy for inter-individual differences in brain serotonin levels, the collaborative effort across research groups within Cimbi underscore its abilities to move biomedical research forward.

Read the entire story here.

Developed through medicinal chemistry, radiochemistry, and animal studies, 2012 was the year where our first “Cimbi”-compound, [¹¹C]Cimbi-36, was taken into humans and tested in healthy volunteers. This milestone builds on several years of development and represents a huge achievement for the center.

Read the entire story here.